Patents by Inventor Andrew P. Combs

Andrew P. Combs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclylamines as PI3K inhibitors
    Patent number: 10376513
    Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: August 13, 2019
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Richard B. Sparks, Andrew P. Combs, Brent Douty, Yun-Long Li, Song Mei, Eddy W. Yue
  • 1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
    Patent number: 10369137
    Abstract: The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: August 6, 2019
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Andrew P. Combs, Eddy W. Yue, Richard B. Sparks, Wenyu Zhu
  • TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS
    Publication number: 20190233435
    Abstract: The present disclosure relates to tricyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: February 1, 2019
    Publication date: August 1, 2019
    Inventors: Andrew P. Combs, Richard B. Sparks
  • MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME
    Publication number: 20190210985
    Abstract: The present invention is directed to modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.
    Type: Application
    Filed: January 10, 2019
    Publication date: July 11, 2019
    Inventors: Andrew P. Combs, Eddy W. Yue
  • TERTIARY ALCOHOLS AS PI3K-y INHIBITORS
    Publication number: 20190152975
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: October 17, 2018
    Publication date: May 23, 2019
    Inventors: Brent Douty, Andrew W. Buesking, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Ravi Kumar Jalluri, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Richard B. Sparks, Eddy W. Yue
  • HETEROCYCLYLAMINES AS PI3K INHIBITORS
    Publication number: 20190134040
    Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Application
    Filed: August 24, 2018
    Publication date: May 9, 2019
    Inventors: Yun-Long Li, Wenqing Yao, Andrew P. Combs, Eddy W. Yue, Song Mei, Wenyu Zhu, Joseph Glenn, Thomas P. Maduskuie, JR., Richard B. Sparks, Brent Douty, Chunhong He
  • HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS
    Publication number: 20190119287
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: October 19, 2018
    Publication date: April 25, 2019
    Inventors: Andrew W. Buesking, Richard B. Sparks, Andrew P. Combs, Brent Douty, Nikoo Falahatpisheh, Lixin Shao, Stacey Shepard, Eddy W. Yue
  • Bicyclic azaheterocyclobenzylamines as PI3K inhibitors
    Patent number: 10259818
    Abstract: The present invention provides bicyclic azaheterocyclobenzylamines of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: April 16, 2019
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Andrew P. Combs, Richard B. Sparks, Thomas P. Maduskuie, Jr.
  • BICYCLIC HETEROARYLAMINOALKYL PHENYL DERIVATIVES AS PI3K INHIBITORS
    Publication number: 20190084997
    Abstract: This application relates to derivatives of Formula I: and pharmaceutically acceptable salts thereof, which are inhibitors of PI3K, and compositions and methods of treatment related thereto.
    Type: Application
    Filed: August 24, 2018
    Publication date: March 21, 2019
    Inventors: Yun-Long Li, Andrew P. Combs
  • Tricyclic heterocycles as bet protein inhibitors
    Patent number: 10227359
    Abstract: The present disclosure relates to tricyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: March 12, 2019
    Assignee: Incyte Corporation
    Inventors: Andrew P. Combs, Richard B. Sparks
  • HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS
    Publication number: 20190062336
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: July 25, 2018
    Publication date: February 28, 2019
    Inventors: Artem Shvartsbart, Stacey Shepard, Andrew P. Combs, Lixin Shao, Nikoo Falahatpisheh, Ge Zou, Andrew W. Buesking, Richard B. Sparks, Eddy W. Yue, Ravi Kumar Jalluri
  • AZA-HETEROARYL COMPOUNDS AS PI3K-GAMMA INHIBITORS
    Publication number: 20190060331
    Abstract: The present invention provides aza-heteroaryl derivatives of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A, W, R4, R5, and R6 are defined herein, that inhibit the activity of phosphoinositide 3-kinases-gamma (PI3K?) and are useful in the treatment of diseases related to the activity of PI3K? including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: June 28, 2018
    Publication date: February 28, 2019
    Inventors: Ge Zou, Andrew P. Combs, Andrew W. Buesking
  • Modulators of indoleamine 2,3-dioxygenase and methods of using the same
    Patent number: 10208002
    Abstract: The present invention is directed to modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: February 19, 2019
    Assignee: Incyte Corporation
    Inventors: Andrew P. Combs, Eddy W. Yue
  • USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS
    Publication number: 20190040067
    Abstract: The present application provides methods of treating PI3K? related disorders using compounds of Formula I: or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: March 2, 2018
    Publication date: February 7, 2019
    Inventors: Yun-Long Li, Wenqing Yao, Andrew P. Combs, Eddy W. Yue, Song Mei, Wenyu Zhu, Joseph Glenn, Thomas P. Maduskuie, JR., Richard B. Sparks, Brent Douty, Chunhong He
  • BICYCLIC AZAHETEROCYCLOBENZYLAMINES AS PI3K INHIBITORS
    Publication number: 20190002470
    Abstract: The present invention provides bicyclic azaheterocyclobenzylamines of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Application
    Filed: February 22, 2018
    Publication date: January 3, 2019
    Inventors: Andrew P. Combs, Richard B. Sparks, Thomas P. Maduskuie, JR.
  • PYRIMIDINONES AS PI3K INHIBITORS
    Publication number: 20180362546
    Abstract: The present invention provides pyrimidinones that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Application
    Filed: April 23, 2018
    Publication date: December 20, 2018
    Inventors: Yun-Long Li, Brian W. Metcalf, Andrew P. Combs
  • TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS
    Publication number: 20180346481
    Abstract: The present invention relates to tricyclic heterocycles of Formula (I): which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: February 27, 2018
    Publication date: December 6, 2018
    Inventors: Andrew P. Combs, Richard B. Sparks, Thomas P. Maduskuie, JR., James D. Rodgers
  • Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-? inhibitors
    Patent number: 10138248
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: November 27, 2018
    Assignee: Incyte Corporation
    Inventors: Andrew W. Buesking, Richard B. Sparks, Andrew P. Combs, Brent Douty, Nikoo Falahatpisheh, Lixin Shao, Stacey Shepard, Eddy W. Yue
  • 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS
    Publication number: 20180312506
    Abstract: The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: March 21, 2018
    Publication date: November 1, 2018
    Inventors: Andrew P. Combs, Thomas P. Maduskuie, JR., Nikoo Falahatpisheh
  • Heterocyclylamines as PI3K inhibitors
    Patent number: 10092570
    Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: October 9, 2018
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Yun-Long Li, Wenqing Yao, Andrew P. Combs, Eddy W. Yue, Song Mei, Wenyu Zhu, Joseph Glenn, Thomas P. Maduskuie, Jr., Richard B. Sparks, Brent Douty, Chunhong He